#USA #Madison #Biologics #Axio BioPharma #AI Biomanufacturing

Axio BioPharma Strengthens Advisory Board for Innovative Biologics Development

In a strategic move to bolster its leadership team, Axio BioPharma Inc., recognized for its role as a cutting-edge biomanufacturing company, has announced the expansion of its advisory board to fuel its AI-centric initiatives in biologics. The inclusion of Patrick Haffey, an accomplished executive in the biopharmaceutical realm, alongside existing advisors Dr. Greg Bleck and Dr. Graham Brearley, forms a powerhouse of expertise aimed at revolutionizing mammalian protein production.

CEO Justin Byers expressed his enthusiasm about this expansion, stating, “We’re excited to welcome Pat to the advisory board alongside Greg and Graham. Together, they bring a tremendous depth of expertise in scaling biologics manufacturing and developing strategic partnerships. Their guidance will be invaluable as we expand our AI-enabled platform and grow our operational footprint.”

A Deep Well of Experience

The advisory board is not merely a collection of names; it represents a wealth of experience in the biologics sector. Dr. Greg Bleck, a veteran with a respectable track record in biotechnology research and development, boasts over 175 biologics currently in clinical trials and holds more than 20 patents. His journey includes co-founding Gala Design, which laid the groundwork for Gala Biotech, along with his pivotal role in pioneering the GPEx® cell line platform used for producing several approved therapies.

Dr. Graham Brearley, with over 30 years of experience in biologics process development and manufacturing operations, adds another layer of depth to the board. His leadership in large-scale facility expansions and managing regulatory processes is invaluable, having overseen more than 100 due diligence initiatives concerning mergers and acquisitions across various regulatory agencies in both the U.S. and Europe.

Patrick Haffey, the newest addition, brings to the table two decades of experience launching and scaling Good Manufacturing Practice (GMP) operations worldwide. In his prior roles at global leaders such as Samsung Biologics and Jubilant Hollister-Stier, Haffey has demonstrated his prowess in facility development, quality assurance, and regulatory compliance. With an impressive capital raising record exceeding $150 million and a strong network of enduring partnerships, he is primed to support Axio’s ambitions in the biomanufacturing domain.

Commitment to Innovation

These advisory board appointments highlight Axio BioPharma's unwavering commitment to innovation and operational excellence within the biopharma landscape. As the company looks towards an expansion of its AI-driven biomanufacturing platform, its ongoing dedication to supporting the next generation of biologic therapies is apparent.

Headquartered in Madison, Wisconsin, Axio BioPharma stands at the forefront of revolutionizing monoclonal antibody production. The company leverages high-throughput production capabilities and proprietary machine learning technologies that enable the prediction of optimal scalable manufacturing processes within hours rather than years. This innovative approach accelerates the development of groundbreaking therapies while notably reducing associated costs, positioning Axio as a crucial partner for biopharma innovators eager to expedite their journey to market.

With deep expertise in antibody manufacturing, protein purification, and bioinformatics, Axio aims to reinforce its partnerships with research entities, diagnostic companies, and therapeutic developers through scalable, U.S.-based production, coupled with enhanced data-driven processes.

Conclusion

As the biomanufacturing landscape continues to evolve, Axio BioPharma's strategic appointments to its advisory board showcase a leading edge in biologics innovation. With experts like Haffey, Bleck, and Brearley on their side, the future looks promising for this AI-focused biomanufacturing company, as it strives to enable biopharma pioneers to deliver life-saving therapies more efficiently and swiftly to those in need.